Helix Biopharma Corp.
Records under this name other than the patents Helix Biopharma Corp. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 4 patents it holds.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,945,529 | Biphasic Lipid-Vesicle Compositions Formerly held In force · High confidence | In force | High confidence | |
| US 8,986,732 | Biphasic Lipid-Vesicle Compositions and Methods for Treating Cervical Dysplasia by Intravaginal Delivery Formerly held In force · High confidence | In force | High confidence | |
| US 8,992,969 | Biphasic Lipid-Vesicle Compositions and Methods for Treating Cervical Dysplasia by Intravaginal Delivery Formerly held In force · Medium confidence | In force | Medium confidence | |
| US 9,011,924 | Biphasic Lipid-Vesicle Compositions and Methods for Treating Cervical Dysplasia by Intravaginal Delivery Formerly held In force · High confidence | In force | High confidence | |
| US 10,159,646 | Biphasic Lipid-Vesicle Compositions and Methods for Treating Cervical Dysplasia by Intravaginal Delivery Formerly held In force · High confidence | In force | High confidence | |
| US 11,466,088 | VEGFR-2 Car Immune Cells to Treat Cancers Lapsed on the fee record Ended Oct 11, 2026 · High confidence | Lapsed on the fee record | Ended Oct 11, 2026 | High confidence |
| US 11,242,386 | CEACAM6 Car Immune Cells to Treat Cancers Lapsed on the fee record Ended Feb 8, 2026 · High confidence | Lapsed on the fee record | Ended Feb 8, 2026 | High confidence |
| US 7,211,250 | Method and Composition for Inhibiting Cancer Cell Growth Term ended Term ended Jul 1, 2024 · High confidence | Term ended | Term ended Jul 1, 2024 | High confidence |
| US 9,296,819 | Antibodies and Conjugates That Target Misfolded Prion Protein Formerly held Lapsed on the fee record Ended Mar 29, 2024 · High confidence | Lapsed on the fee record | Ended Mar 29, 2024 | High confidence |
| US 7,264,800 | Method and Composition for Inhibiting Cancer Cell Growth Term ended Term ended Feb 21, 2024 · High confidence | Term ended | Term ended Feb 21, 2024 | High confidence |